Medifast (NYSE:MED – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Monday. The company provided EPS guidance of -0.650–0.150 for the period, compared to the consensus EPS estimate of -0.620. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $68.0 million. Medifast also updated its FY 2026 guidance to -1.750–0.250 EPS.
Medifast Stock Down 1.1%
NYSE:MED opened at $9.72 on Tuesday. The company has a market capitalization of $108.13 million, a PE ratio of -5.31 and a beta of 0.65. Medifast has a 52-week low of $9.22 and a 52-week high of $15.11. The stock’s 50 day moving average price is $11.05 and its 200 day moving average price is $11.04.
Medifast (NYSE:MED – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The firm had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, sell-side analysts anticipate that Medifast will post -1.97 EPS for the current fiscal year.
Analyst Ratings Changes
Insider Activity
In other Medifast news, Director Scott Schlackman purchased 2,500 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the transaction, the director directly owned 30,549 shares of the company’s stock, valued at $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 3.70% of the stock is owned by company insiders.
Trending Headlines about Medifast
Here are the key news stories impacting Medifast this week:
- Positive Sentiment: Medifast reported a second-quarter loss of $0.28 per share, substantially better than the consensus estimate for a $0.65–$0.67 loss. Revenue of $76.4 million also exceeded estimates of approximately $72.7 million. Medifast Reports Q2 Loss, Beats Revenue Estimates
- Positive Sentiment: Management’s full-year 2026 EPS outlook of a $0.25 to $1.75 loss is better than the consensus estimate for a $1.87 loss. The company maintained a sizable liquidity position, ending the quarter with $169.8 million in cash, equivalents and investments and no debt. Medifast Announces Second Quarter 2026 Financial Results
- Positive Sentiment: The company highlighted its “3.0” metabolic-health strategy, stabilized revenue trends and improving productivity among its independent coaches. Chief Executive Officer Daniel Chard also purchased 17,678 shares in the past six months, a potential signal of management confidence. Medifast 3.0 Strategy and Coach Productivity
- Neutral Sentiment: Third-quarter guidance calls for revenue of $60 million to $80 million and an adjusted loss of $0.15 to $0.65 per share. The ranges broadly bracket analyst expectations of $68 million in revenue and a $0.62 loss, suggesting limited near-term visibility. Medifast Q2 2026 Earnings Call Transcript
- Negative Sentiment: Revenue fell 27.6% year over year to $76.4 million, while the company swung to a $3.1 million net loss from $2.5 million of profit a year earlier. Active earning coaches plunged 48.7% to 11,700, indicating continued customer-acquisition and distribution challenges.
Institutional Trading of Medifast
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MED. Corient Private Wealth LLC purchased a new stake in shares of Medifast during the fourth quarter worth about $139,000. Empowered Funds LLC grew its stake in Medifast by 11.1% in the 4th quarter. Empowered Funds LLC now owns 44,773 shares of the specialty retailer’s stock worth $478,000 after acquiring an additional 4,462 shares during the period. Man Group plc grew its stake in Medifast by 10.8% in the 4th quarter. Man Group plc now owns 236,500 shares of the specialty retailer’s stock worth $2,526,000 after acquiring an additional 23,070 shares during the period. Trexquant Investment LP raised its holdings in Medifast by 88.0% in the 4th quarter. Trexquant Investment LP now owns 126,959 shares of the specialty retailer’s stock valued at $1,356,000 after acquiring an additional 59,439 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Medifast by 24.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,905 shares of the specialty retailer’s stock worth $245,000 after purchasing an additional 4,500 shares during the period. Hedge funds and other institutional investors own 95.51% of the company’s stock.
About Medifast
Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
Read More
- Five stocks we like better than Medifast
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.
